Table 1 Basic general and oncological characteristics according to state of postoperative Tyrosinkinase Inhibitor (TKI) therapy
Variables | Overall (n = 35) | TKI (+) (n = 16) | TKI (-) (n = 19) | p-value |
|---|---|---|---|---|
Median Age (years) | 65 (59–71) | 64.5 (58–71) | 69 (62–71) | 0.160a |
Gender | 24:11 | 12:4 | 12:7 | 0.452d |
Male/female | (68.6/31.4 %) | (34.3:11.4 %) | (34.3:20 %) | |
Median Body mass index (kg/m2) | 26.5 (24.5–28.0) | 26.9 (26.0–28.3) | 25.9 (24.2–27.7) | 0.349a |
ECOG performance status (%) | ||||
0 | 29 (82.9 %) | 15 (42.9 %) | 14 (40 %) | 0.117d |
1 | 6 (17.1 %) | 1 (2.9 %) | 5 (14.3 %) | |
Primary tumor characteristics | ||||
Right side/left side; n (%) | 21/14 (60 %:40 %) | 7/9 (20 %:25.7 %) | 14/5 (40 %:14.3) | 0.072d |
Primary tumor histology | ||||
Clear cell | 25 (71.4 %) | 10 (28.6 %) | 15 (42.9 %) | 0.283c |
Non-clear cell | 10 (28.6 %) | 6 (17.1 %) | 4 (11.5 %) | |
Primary tumor T-stage | ||||
Stage 1–2 | 16 (45.8 %) | 8 (22.9 %) | 8 (22.9 %) | 0.640c |
Stage 3–4 | 19 (54.2 %) | 11 (31.3 %) | 8 (22.9 %) | |
Primary tumor grading | ||||
Low (Fuhrmann 1–2) | 24 (68.6 %) | 12 (34.3 %) | 12 (34.3 %) | 0.452d |
High (Fuhrmann 3–4) | 11 (31.4 %) | 4 (11.4 %) | 7 (20 %) | |
Liver tumor distribution | ||||
Unilobular/Multilobular | 28:7 (80 %:20 %) | 14:2 (40 %:14.3 %) | 14:5 (40 %:5.7 %) | 0.309d |
Median tumor size (cm) | 4.4 (2.9–6.0) | 3.9 (2.5–4.5) | 5.6 (3.0–7.5) | 0.094a |
Mean number of hepatic tumor lesions | 1.70 (1–5) | 1.64 (1–4) | 1.74 (1–5) | 0.813b |
Median weight of resected liver (g) | 212.5 (39.2–652.5) | 81.4 (15.5–265.0) | 290 (70–916.3) | 0.138a |
Timing of liver metastases | ||||
Synchronous/ | 6 (17.1 %) | 4 (11.4 %) | 2 (5.7 %) | 0.258d |
metachronous | 29 (82.9 %) | 12 (34.3) | 17 (48.6 %) | |
Extrahepatic disease at time of liver-directed therapy | ||||
Yes | 7 (20 %) | 5 (14.3 %) | 2 (5.7 %) | 0.127d |
No | 28 (80 %) | 11 (31.4 %) | 17 (48.6 %) | |